GILEAD SCIENCES, INC. quarterly report, Q2 FY2005

Abrir documento

Business Context and Reporting Period

Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: Gilead is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for life-threatening infectious diseases. Key products include HIV treatments (Viread, Truvada, Emtriva), Hepatitis B treatment (Hepsera), and antifungal therapy (AmBisome). The company also earns royalties from partners such as Roche (Tamiflu) and Eyetech (Macugen).

Key Financial Metrics

Metric Three Months Ended June 30, 2005 Six Months Ended June 30, 2005
Total Revenues $495.3 million $925.7 million
Net Income $196.0 million $353.1 million
Diluted EPS $0.41 $0.75
Operating Cash Flow $291.6 million (Q2 only) $518.9 million (YTD)
Cash & Marketable Securities $1.79 billion (Balance Sheet) N/A
Product Gross Margin 86% 86%
Long-Term Debt $0.3 million N/A

Material Changes vs. Prior Period

  • Revenue Growth: Total revenues increased 55% year-over-year for the quarter and 47% for the six-month period. Product sales rose 50% in Q2, driven primarily by a 61% increase in HIV product sales.
  • Product Performance:
    • Truvada: Generated $123.1 million in Q2 sales (new product, no prior year comparison), representing over 50% of U.S. HIV sales.
    • Viread: Sales increased 6% in Q2 to $209.1 million, driven by European volume growth despite a 14% volume decrease in the U.S. due to patient switching to Truvada.
    • Hepsera: Sales surged 64% in Q2 to $45.8 million, largely due to a 95% volume increase in Europe.
  • Royalty Revenue: Royalty and contract revenue jumped 129% in Q2 to $46.8 million, primarily due to $36.0 million in royalties from Roche for Tamiflu sales in Q1 2005 (recognized in Q2) and a $7.0 million milestone from Eyetech.
  • Profitability: Net income increased 76% in Q2 and 56% YTD compared to 2004. Operating income rose 75% in Q2.
  • Expenses: R&D expenses increased 31% in Q2, partly due to a $15.0 million upfront license fee for an HIV integrase inhibitor from Japan Tobacco. SG&A expenses increased 29% due to higher headcount and marketing activities.

Guidance, Outlook, and Risks

Management Commentary and Guidance

  • 2005 Revenue Outlook:
    • HIV Products: $1.275 billion to $1.325 billion.
    • AmBisome: $205 million to $215 million.
    • Hepsera: $160 million to $180 million (adjusted for new competition).
  • 2005 Expense Outlook:
    • R&D: $265 million to $285 million (includes a $15.0 million one-time payment to Emory).
    • SG&A: $365 million to $385 million (includes European headquarters relocation costs).
  • Capital Expenditures: Expected to be $55 million to $65 million for the full year.

Significant Risks and Contingencies

  • Roche Dispute: Gilead delivered a notice of termination to Roche on June 23, 2005, citing material breach of the Tamiflu agreement, including an alleged $18.2 million underpayment of royalties for 2001-2003. The outcome of potential arbitration is uncertain.
  • Emory Royalty Buyout: Subsequent to the quarter end (July 21, 2005), Gilead and Royalty Pharma paid $525.0 million to Emory University to buy out future emtricitabine royalties. Gilead's share ($341.3 million) will be capitalized and amortized to cost of goods sold.
  • European Relocation: Relocation of European headquarters from Paris to London is expected to cost $10 million to $13 million, primarily expensed in the second half of 2005.
  • Accounting Changes: Gilead expects to adopt SFAS 123R (Share-Based Payment) on January 1, 2006, which will materially impact reported earnings and cash flows.
  • Competition: Increased competition noted for Hepsera (BMS's Baraclude) and AmBisome (Merck and Pfizer products).

Investor Verification Checklist

  • Roche Termination Status: Verify the current status of the dispute with Roche regarding Tamiflu royalties and the potential impact on future royalty streams.
  • Emory Buyout Impact: Confirm the amortization schedule for the $341.3 million Emory royalty buyout and its effect on future gross margins.
  • Truvada Market Share: Monitor prescription data to ensure Truvada continues to capture market share from Viread and competitors as projected.
  • European Currency Exposure: Assess the impact of foreign exchange fluctuations on reported revenues, given significant European sales.
  • Relocation Costs: Track the actual costs incurred for the European headquarters relocation against the $10-$13 million estimate.